

Gaucher Disease Pipeline Insights 2025 Market - 2026-2032

<https://marketpublishers.com/r/G5FB0CFBEB7BEN.html>

Date: March 2025

Pages: 0

Price: US\$ 3,400.00 (Single User License)

ID: G5FB0CFBEB7BEN

Contents

1. EXECUTIVE SUMMARY

- Introduction

2. GAUCHER DISEASE: OVERVIEW

- Introduction
- Causes
- Pathophysiology
- Signs and Symptoms
- Diagnosis
- Treatment

3. PIPELINE ANALYSIS

- Assessment by Phase
 - o Phase I Clinical Trials
 - o Phase II Clinical Trials
 - o Phase III Clinical Trials
- Assessment by Mechanism of Action
 - o Enzyme Replacement Therapy (ERT)
 - o Substrate Reduction Therapy (SRT)
 - o Gene Therapy
- Assessment by Route of Administration
 - o Intravenous
 - o Oral

4. LIST OF KEY COMPANIES INVOLVED

- CANbridge Life Sciences Ltd. *
- o Drug Profile
- Spur Therapeutics
- Prevail Therapeutics
- Sanofi
- Lingyi Biotech Co., Ltd.
- Yuhan Corporation

5. REGULATORY DESIGNATIONS

- Orphan Drug Designation
- Fastrack Designation
- Breakthrough Therapy Designation
- Priority Review
- PRIME Designation
- RMAT Designation
- ATMP Designation

6. CLINICAL DATA READOUTS

- Trial Initiation
- Trial Completion
- Safety/Efficacy- Data Readouts
- Discontinued Products

7. ESTIMATED APPROVALS

8. MERGER AND ACQUISITIONS

9. FUTURE PERSPECTIVES AND CONCLUSION

I would like to order

Product name: Gaucher Disease Pipeline Insights 2025 Market - 2026-2032

Product link: <https://marketpublishers.com/r/G5FB0CFBEB7BEN.html>

Price: US\$ 3,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G5FB0CFBEB7BEN.html>